Entity

Time filter

Source Type

New York City, United States

Mason A.R.,The University of York
The Cochrane database of systematic reviews | Year: 2013

Chronic plaque psoriasis is the most common type of psoriasis, and it is characterised by redness, thickness, and scaling. First-line management of chronic plaque psoriasis is with topical treatments, including vitamin D analogues, topical corticosteroids, tar-based preparations, dithranol, salicylic acid, and topical retinoids. To compare the effectiveness, tolerability, and safety of topical treatments for chronic plaque psoriasis, relative to placebo, and to similarly compare vitamin D analogues (used alone or in combination) Register, CENTRAL in The Cochrane Library (2011, Issue 2), MEDLINE (from 1948), EMBASE (from 1980), Science Citation Index (from 2008), Conference Proceedings Citation Index - Science (from 2008), BIOSIS (from 1993), Dissertation Abstracts via DialogClassic (all publication years), and Inside Conferences (all publication years).We identified ongoing and unpublished studies from the UK Clinical Research Network (from 2005).Final update searches for both RCTs and adverse effects were undertaken in August 2012. Although it has not been possible to against placebo or against vitamin D analogues (used alone or in combination) in people with chronic plaque psoriasis. One author the standardised mean difference (SMD) ranging from -0.67 (95% CI -1.04 to -0.30; 1 study, 119 participants) for twice-daily becocalcidiol to SMD -1.66 (95% CI -2.66 to -0.67; 1 study, 11 participants) for corticosteroids (SMD -0.89; 95% CI -1.06 to -0.72; I2 statistic = 65.1%; 14 studies, 2011 participants) had smaller benefits than very potent corticosteroids (SMD -1.56; 95% CI -1.87 to -1.26); I2 statistic = 81.7%; 10 studies, 1264 participants). On a of evidence about the risk of skin dermal atrophy. Further research is required to inform long-term maintenance treatment and provide appropriate safety data. Source


Patent
The University Of York | Date: 2013-07-15

The device (


Patent
Japan Science, Technology Agency and The University Of York | Date: 2013-07-25

A spin rotary member includes a substrate, a spin injector made of a ferromagnetic material magnetized in a substrate in-plane direction, and provided on the substrate, a spin rotor made of a ferromagnetic material having a magnetic moment rotatable in the substrate in-plane direction, and provided on the substrate, being separated from the spin injector, a channel part made of a non-magnetic material, arranged between the spin injector and the spin rotor, and bonded with the spin injector and the spin rotor directly or through an insulating layer, and a spin rotation control part configured to control a rotation direction of spin of the channel part.


Patent
The University Of York | Date: 2013-07-15

The invention disclosed herein is to a device to assist in the determination of the presence and type of dyskinesia in a patient. The device includes a sensor, removably attachable to a patients body, such as on a limb or torso, the sensor being capable of detecting 3-D motion. Data generated by the sensor is transferred to and retained in a data retention means. A processing means is included to process the generated data, along with a look-up table of processed data for already known dyskinesia conditions for comparison, The processing means employs an evolutionary algorithm in the classification of the data. Output means display the diagnosed condition to a user.


Patent
The University Of York | Date: 2013-12-23

A mesoporous material is derived from a polysaccharide by thermally assisted partial carbonisation after expansion. The polysaccharide is an acid containing polysaccharide or mixture of polysaccharides.

Discover hidden collaborations